BOXED O
WARNING O
: O
WARNING O
: O
HEMORRHAGE O
, O
GASTROINTESTINAL O
PERFORATION O
, O
AND O
IMPAIRED O
WOUND O
HEALING O
WARNING O
: O
HEMORRHAGE O
, O
GASTROINTESTINAL O
PERFORATION O
, O
AND O
IMPAIRED O
WOUND O
HEALING O
Hemorrhage B-NonOSE_AE
: O
CYRAMZA O
increased O
the O
risk O
of O
hemorrhage B-OSE_Labeled_AE
and O
gastrointestinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
including O
severe O
and O
sometimes O
fatal B-NonOSE_AE
hemorrhagic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
. O

Permanently O
discontinue O
CYRAMZA O
in O
patients O
who O
experience O
severe O
bleeding B-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
, O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

Gastrointestinal B-NonOSE_AE
Perforation I-NonOSE_AE
: O
CYRAMZA O
can O
increase O
the O
risk O
of O
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
, O
a O
potentially O
fatal B-NonOSE_AE
event O
. O

Permanently O
discontinue O
CYRAMZA O
in O
patients O
who O
experience O
a O
gastrointestinal B-NonOSE_AE
perforation I-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
, O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
. O

Impaired B-NonOSE_AE
Wound I-NonOSE_AE
Healing I-NonOSE_AE
: O
Impaired B-OSE_Labeled_AE
wound I-OSE_Labeled_AE
healing I-OSE_Labeled_AE
can O
occur O
with O
antibodies O
inhibiting O
the O
VEGF O
pathway O
. O

Discontinue O
CYRAMZA O
therapy O
in O
patients O
with O
impaired B-NonOSE_AE
wound I-NonOSE_AE
healing I-NonOSE_AE
. O

Withhold O
CYRAMZA O
prior O
to O
surgery O
and O
discontinue O
CYRAMZA O
if O
a O
patient O
develops O
wound B-NonOSE_AE
healing I-NonOSE_AE
complications I-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
, O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
. O

EXCERPT O
: O
WARNING O
: O
HEMORRHAGE O
, O
GASTROINTESTINAL O
PERFORATION O
, O
AND O
IMPAIRED O
WOUND O
HEALING O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

* O
Hemorrhage O
: O
CYRAMZA O
increased O
the O
risk O
of O
hemorrhage O
, O
and O
gastrointestinal O
hemorrhage O
, O
including O
severe O
and O
sometimes O
fatal O
hemorrhagic O
events O
. O

Permanently O
discontinue O
CYRAMZA O
in O
patients O
who O
experience O
severe O
bleeding O
. O

( O
2.3 O
, O
5.1 O
) O
* O
Gastrointestinal O
Perforation O
: O
Permanently O
discontinue O
CYRAMZA O
in O
patients O
who O
experience O
a O
gastrointestinal O
perforation O
. O

( O
2.3 O
, O
5.5 O
) O
* O
Impaired O
Wound O
Healing O
: O
Withhold O
CYRAMZA O
prior O
to O
surgery O
and O
discontinue O
CYRAMZA O
if O
a O
patient O
develops O
wound O
healing O
complications O
( O
2.3 O
, O
5.6 O
) O

